^
Association details:
| Biomarker: | CD8 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes
Published date:
05/24/2022
Excerpt:
Targeted sequencing and histopathological analysis (CD8 and CD20 immunohistochemistry) were performed on subtypes of metastatic melanoma...treated with ICI (pembrolizumab, ipilimumab or nivolumab)...Progression-free survival (PFS) was significantly associated with high CD8 expression (p = 0.025) and mutations in DNA damage repair (DDR) pathway genes (p = 0.012) in all subtypes but not with CD20 expression.
DOI:
10.3390/medsci10020026
Source:
Title:
CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma
Published date:
01/11/2021
Excerpt:
Patients with locally/regionally advanced melanoma were treated with neoadjuvant combination immunotherapy with high-dose interferon α-2b (HDI) and ipilimumab in a phase I clinical trial...increased expression of baseline pro-inflammatory genes CCL19, CD3D, CD8A, CD22, LY9, IL12RB1, C1S, C7, AMICA1, TIAM1, TIGIT, THY1 was associated with longer OS (p < 0.05).
Secondary therapy:
interferon alfa 2b
DOI:
10.1371/journal.pone.0245287
Source:
Title:
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
Excerpt:
A 3+3 dose escalation design was used with 9, 15, 18 and 24 Gy dose of radiotherapy at week 4 combined with 10 mg/kg ipilimumab every 3 weeks for four doses….The median progression-free survival (PFS) (95% CI) was 0.4 (0.2-1.4)….Increased CD8+ was significantly associated with PFS.
DOI:
10.1136/jitc-2020-000627
